MultiCare Regional Cancer Center

Below are some of the SCCA clinical trials now being offered for patients at MultiCare Regional Cancer Center. If you have any questions about these or other trials, please contact MultiCare Regional Cancer Center.

Breast Cancer (Newly Diagnosed)

• Triple Negative (6628)
  Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
• WBI Versus PBI for Women with Stage 0, I or II Breast Cancer (NSABP B-39)
  A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer
• Herceptin + Radiation Therapy for HER2-Positive Resected by Lumpectomy (NSABP B-43)
  A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
• Chemo w/wo Traztuzumab After Surgery for Invasive Breast Cancer (NSABP B-47)
  A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab (Herceptin) in Women with Node-Positive or High-Risk Node-Negative HER@-Low Invasive Breast Cancer

Breast Cancer (Recurrent/Metastatic)

• Triple Negative (6628)
  Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib
• WBI Versus PBI for Women with Stage 0, I or II Breast Cancer (NSABP B-39)
  A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I or II Breast Cancer

Gastric, Gastroesophageal and Esophageal Cancer (Metastatic or Locally Advanced)

• Ramucirumab for Gastric, Esophageal and GE Juntion (7575)                         Randomized, Placebo-Controlled, double-blind Phase 2 study of mFOLFOX6 chemotherapy plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 plus placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal junction or Stomach

Gynecologic Cancer (Newly Diagnosed)

• Radiation vs Brachytherapy for Endometrial Carcinoma (GOG 249)
  A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma
• Paclitaxel + Carboplatin vs Ifosfamide + Paclitaxel for Uterine or Ovarian Cancer (GOG 261)
  A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
• Temsirolimus + Carboplatin/Paclitaxel Stage III-IV Clear Cell Carcinoma of the Ovary (GOG 268)
  A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: NSC#683864, IND#61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus (CCI-779) Consolidation as First-Line Therapy in the Treatment of Stage III-IV Clear Cell Carcinoma of the Ovary
• Chemotherapy + Pelvic Radiation for High-Risk Early-Stage Cervical Cancer (GOG/ RTOG 0724)
  Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy

Gynecologic Cancer (Recurrent/Metastatic)

• Paclitaxel with or without Pazopanib in Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer  (GOG 186-J)
  A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
• Paclitaxel vs Polyglutamate Paclitaxel (GOG 212)
  A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
• Carboplatin + Paclitaxel w/wo Bevacizumab After Surgery (GOG 213)
  A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
• Ceciranib Maleate in Recurrent or Persistent Endometrial Cancer (GOG 229-J)
  A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND# 72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
• BIBF 1120 in Recurrent or Persistent Endometrial Cancer (GOG 229-K)
  Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
• Radiation vs Brachytherapy for Endometrial Carcinoma (GOG 249)
  A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma
• Combination Chemotherapy + Radiation Therapy for Stage III/IVA Endometrial Cancer (GOG 0258)
  A Randomized Phase III Trialof Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma
• Elesclomol Sodium and Paclitaxel for Recuyrrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (GOG 260)
  A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
• Paclitaxel + Carboplatin vs Ifosfamide + Paclitaxel for Uterine or Ovarian Cancer (GOG 261)
  A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary

Head and Neck Cancer (Recurrent/Metastatic)

• Erlotinib + Cisplatin/Radiotherapy (6106)
  A Multicenter Randomized Phase II Study of Erlotinib, Cisplatin and Radiotherapy Versus Cisplatin and Radiotherapy in Patients With Stage III and IV Squamous Cell Carcinoma of the Head and Neck

Leukemia (Newly Diagnosed)

• Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
  A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small LymphoCtic Lymphoma (SLL)

Leukemia (Recurrent/Metastatic)

• Bexxar Consolidation CLL or SLL (PSOC 2301)
  A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission

Lymphoma (Newly Diagnosed)

• Vorinostat + Chemotherapy for CLL or SLL (PSOC-2401)
  A Phase I/II Study of Fludarabine (F), Cyclophosphamide ©), Rituximab ®), and Vorinostat (V) Followed by RV Maintenance Therapy in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphoctic Lymphoma (SLL)

Lymphoma (Recurrent/Metastatic)

• Bexxar Consolidation CLL or SLL (PSOC 2301)
  A Study of 131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission
• TREC for Relapsed or Refractory Lymphoid Malignancies (PSOC 2502)
  A Phase I Trial of Bendamustine/Treanda, Rituxmab, Etoposide, and Carboplatin (TREC) for Patients With Relapsed or Refractory Lymphoid Malignancies

Prostate Cancer

• SCORE (30824)
  SCORE -- Assessment of Mood, Information Processing and Quality of Life in Prostate Cancer Survivors and Patients